Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 13, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Lipo-MIT combination regimen

"Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed."

Trial Locations (1)

226001

RECRUITING

Affiliated Hospital of Nantong University, Nantong

All Listed Sponsors
lead

Affiliated Hospital of Nantong University

OTHER